Abstract

Remdesivir (RDV) is the only antiviral treatment conditionally approved to treat COVID-19 hospitalized patients (1). In Mexico, RDV received an Emergency Use Authorization on March 2021 for hospitalized adults with a confirmed diagnosis of COVID-19 (2). This study assessed to conduct a CEA of the use of RDV in hospitalized patients compared to the standard of care (SoC) in the Mexican context.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call